Abstract
| Language | English |
|---|---|
| Title of host publication | Advances in Prostate Cancer |
| Place of Publication | London |
| Pages | 275-304 |
| Number of pages | 30 |
| DOIs | |
| Publication status | Published - 16 Jan 2013 |
Fingerprint
Keywords
- CYP17
- CYP17 inhibitors
- prostate cancer treatment
Cite this
}
Steroidal CYP17 inhibitors for prostate cancer treatment : from concept to clinic. / Salvador, Jorge A. R.; Moreira, Vania M.; Silvestre, Samuel M.
Advances in Prostate Cancer. London, 2013. p. 275-304.Research output: Chapter in Book/Report/Conference proceeding › Chapter
TY - CHAP
T1 - Steroidal CYP17 inhibitors for prostate cancer treatment
T2 - from concept to clinic
AU - Salvador, Jorge A. R.
AU - Moreira, Vania M.
AU - Silvestre, Samuel M.
PY - 2013/1/16
Y1 - 2013/1/16
N2 - The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.
AB - The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.
KW - CYP17
KW - CYP17 inhibitors
KW - prostate cancer treatment
U2 - 10.5772/52290
DO - 10.5772/52290
M3 - Chapter
SN - 978-953-51-0932-7
SP - 275
EP - 304
BT - Advances in Prostate Cancer
CY - London
ER -